Format

Send to

Choose Destination
J Glob Antimicrob Resist. 2016 Dec;7:106-109. doi: 10.1016/j.jgar.2016.07.016. Epub 2016 Sep 15.

Promising in vitro and in vivo inhibition of multidrug-resistant Helicobacter pylori by linezolid and novel oxazolidinone analogues.

Author information

1
General Surgery Department, Beijing Tian Tan Hospital, Capital Medical University, Beijing 100050, China.
2
Department of Clinical Laboratory, PLA 309 Hospital, Beijing 100091, China.
3
Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University), Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: yanfangzhao@126.com.

Abstract

The objective of this study was to investigate the prevalence of drug-resistant Helicobacter pylori in Beijing Tian Tan Hospital (Beijing, China) and to determine the susceptibility of H. pylori to linezolid and novel oxazolidinone analogues. Minimum inhibitory concentrations (MICs) of amoxicillin, clarithromycin, metronidazole, ciprofloxacin, tetracycline and levofloxacin against H. pylori were determined by Etest. The in vitro antibacterial activities of linezolid and novel oxazolidinone analogues were assessed by the disk diffusion method. In vivo antibacterial activities were determined by intragastric administration and stomach CFU counting. Drug resistance patterns were serious among clinical H. pylori isolates, with a rate of multidrug-resistant H. pylori of 10.1%. Linezolid was observed to exhibit in vitro activity, with MICs ranging from ≤0.25mg/L to 32mg/L against clinical H. pylori isolates (MIC50, 2mg/L; MIC90, 8mg/L). The oxazolidinone analogue sy142 demonstrated better antimicrobial activity than linezolid in vitro. These results indicate that oxazolidinones may be appropriate agents to treat drug-resistant H. pylori. Further clinical trials should be performed to confirm this.

KEYWORDS:

Antimicrobial agent; Helicobacter pylori; Multidrug resistance; Oxazolidinone

PMID:
27718441
DOI:
10.1016/j.jgar.2016.07.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center